4.4 Review

Allogeneic Chimeric Antigen Receptor Therapy in Lymphoma

期刊

CURRENT TREATMENT OPTIONS IN ONCOLOGY
卷 23, 期 2, 页码 171-187

出版社

SPRINGER
DOI: 10.1007/s11864-021-00920-6

关键词

CAR-T; Allogeneic CAR-T; Non-Hodgkin lymphoma

类别

向作者/读者索取更多资源

Allogeneic CAR-T therapies have advantages over autologous CAR-T therapies, such as easier accessibility and more stable quality, but they also have complications and require genomic editing. Further research and clinical trials are needed.
Opinion statement The therapeutic armamentarium has significantly expanded since the approval of various CD19-targeting chimeric antigen receptor T cell (CAR-T) therapies in non-Hodgkin lymphoma (NHL). These CAR-Ts are patient-specific and require a complex, resource, and time-consuming process. While this appears promising, autologous CAR-Ts are limited due to the lack of accessibility, manufacturing delays, and variable product quality. To overcome these, allogeneic (allo) CARs from healthy donors appear appealing. These can be immediately available as off the shelf ready-to-use products of standardized and superior quality exempt from the effects of an immunosuppressive tumor microenvironment and prior treatments, and potentially with lower healthcare utilization using industrialized scale production. Allogeneic CARs, however, are not devoid of complications and require genomic editing, especially with alpha beta T cells to avoid graft versus host disease (GvHD) and allo-rejection by the recipient's immune system. Tools for genomic editing such as TALEN and CRISPR provide promise to develop truly off the shelf universal CARs and further advance the field of cellular immunotherapy. Several allogeneic CARs are currently in early phase clinical trials, and preliminary data is encouraging. Longer follow-up is required to truly assess the feasibility and safety of these techniques in the patients. This review focuses on the strategies for developing allogeneic CARs along with cell sources and clinical experience thus far in lymphoma.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据